MannKind Corporation (MNKD) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in MannKind (MNKD) by buying shares or fractional shares at any major US broker, through a biotech or small-cap ETF that holds it, or as one holding in a thematic basket. MannKind is a commercial-stage biopharmaceutical company focused on inhaled and endocrine and rare-disease therapies: it markets Afrezza (inhaled insulin) and Furoscix, earns royalties from Tyvaso DPI (a dry-powder inhaled therapy partnered with United Therapeutics), and is developing a pipeline for conditions like pulmonary fibrosis. The single most important thing to understand is that MannKind is a smaller, higher-risk pharma whose value hinges heavily on the growth of Tyvaso DPI royalties plus product launches and FDA decisions, so results and the share price can swing on clinical, regulatory, and commercial news.
MNKD stock price
As of 2026-07-14, MannKind Corporation (MNKD) last closed at $3.98, down 1.1% over the past year. Over the past 52 weeks it has traded between $2.28 and $6.21.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or MannKind Corporation's investor relations page. Walnut is informational, not investment advice.
What does MannKind Corporation (MNKD) do?
MannKind Corporation is a biopharmaceutical company built around its proprietary Technosphere dry-powder inhalation platform and, more recently, endocrine and rare-disease products. Its best-known product is Afrezza, an inhaled mealtime insulin for diabetes, but the larger financial driver has become royalty revenue from Tyvaso DPI, a dry-powder inhaled treatment for pulmonary arterial hypertension and pulmonary fibrosis that United Therapeutics markets under a partnership using MannKind's inhalation technology. MannKind also markets Furoscix, an at-home subcutaneous furosemide therapy for fluid overload associated with conditions like heart failure, which has been ramping quickly. This mix of a growing royalty stream plus its own commercial products distinguishes MannKind from pre-revenue biotechs.
In Q1 2026 MannKind reported total revenue around $90 million, up roughly 15% year over year, driven by Tyvaso DPI royalties (up about 9% to roughly $33 million), Afrezza sales (around $15 million), and Furoscix sales (around $15.5 million, with doses dispensed up sharply). The company recorded a net loss in the quarter as it invested in growth, and it has pointed to a roughly $450 million revenue run-rate ambition supported by product launches and pipeline catalysts. Key catalysts include an Afrezza pediatric indication decision, a Furoscix autoinjector regulatory decision, and pipeline programs such as an inhaled nintedanib (MNKD-201) for idiopathic pulmonary fibrosis and a collaboration with United Therapeutics on an inhaled ralinepag. The investment case combines a durable Tyvaso DPI royalty stream with the higher-risk, higher-reward nature of product launches and clinical readouts typical of smaller biopharma.
What's driving MannKind Corporation (MNKD)?
1. Tyvaso DPI royalties
The most important financial driver is royalty revenue from Tyvaso DPI, which United Therapeutics markets using MannKind's inhalation technology. As Tyvaso DPI expands across pulmonary hypertension and fibrosis indications, MannKind's royalties grow with limited additional cost, making this a high-margin, recurring stream. Continued adoption by United Therapeutics is central to MannKind's earnings and the durability of its cash flow.
2. Furoscix and Afrezza commercial products
MannKind markets Furoscix, an at-home fluid-overload therapy that has been ramping quickly with doses dispensed rising sharply, and Afrezza inhaled insulin. Growing these owned products diversifies revenue beyond royalties and gives MannKind direct commercial leverage. Execution on Furoscix's launch trajectory and any expansion of Afrezza, including a potential pediatric indication, are important swing factors.
3. Regulatory catalysts
MannKind's near-term value is shaped by FDA decisions, including an Afrezza pediatric indication and a Furoscix autoinjector (ReadyFlow) decision, each with target action dates in 2026. Approvals could expand addressable markets and ease of use; setbacks could weigh on the shares. As with most smaller biopharma, binary regulatory events are a defining feature of the risk-reward profile.
4. Endocrine and pulmonary pipeline
The company is advancing a pipeline including an inhaled nintedanib (MNKD-201) for idiopathic pulmonary fibrosis and a collaboration with United Therapeutics on an inhaled ralinepag, extending its Technosphere platform into new therapies. Positive clinical readouts could add long-term value, while failures are common in drug development. The pipeline is the higher-risk, higher-reward layer atop the commercial base.
What are the risks to MannKind Corporation (MNKD)?
The dominant risk is concentration and dependence on partners and catalysts: a large share of high-margin revenue comes from Tyvaso DPI royalties controlled by United Therapeutics, so any slowdown, competition, or change in that product's trajectory would hit MannKind directly. Its owned products, Afrezza and Furoscix, face commercial-execution risk, reimbursement and payer hurdles, and competition, and MannKind has a history of losses, so profitability is not assured. Clinical and regulatory risk is significant: pipeline programs can fail in trials, and FDA decisions can go against the company. As a smaller biopharma, it carries financing risk (it has historically relied on debt and equity), and its shares can be volatile around data and approval events. Broader biotech sentiment and interest rates also affect valuation.
How is MannKind Corporation (MNKD) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see MannKind Corporation's investor relations page or your broker.
- Revenue trend: Q1 2026 total revenue around $90 million, up roughly 15% year over year
- Revenue drivers: Tyvaso DPI royalties (~$33M), Afrezza (~$15M), and Furoscix (~$15.5M) in Q1 2026
- Profitability: Reported a net loss in Q1 2026 while investing in growth; profitability is not yet consistent
- Ambition: Management has pointed to a roughly $450 million revenue run-rate goal supported by launches and catalysts
- Catalysts: 2026 FDA decisions on Afrezza pediatric use and the Furoscix autoinjector, plus pipeline readouts
- Balance sheet: Smaller biopharma that has historically relied on debt and equity financing; watch cash and debt levels
These figures are approximate and tied to the asOf date; verify live numbers before acting. MannKind is valued as a catalyst-driven biopharma, so its shares hinge on the durability of Tyvaso DPI royalties plus the success of product launches and pipeline readouts rather than a stable earnings multiple. Binary regulatory and clinical events can move the stock sharply, so judge it on catalysts and cash runway as much as current revenue.
Who competes with MannKind Corporation (MNKD)?
Diabetes and insulin therapies
For Afrezza, MannKind competes with the large insulin makers Novo Nordisk and Eli Lilly and with Sanofi, whose injectable and other insulins dominate diabetes care. These giants have vast scale and payer relationships, so Afrezza's inhaled approach competes as a differentiated but niche option against entrenched injectable standards.
Pulmonary and rare-disease therapies
MannKind's pulmonary interests, including its Tyvaso DPI partnership and pipeline programs for pulmonary fibrosis, sit in a space with players like United Therapeutics (its partner), Boehringer Ingelheim (nintedanib), and other rare-disease and respiratory drug developers. Success depends on clinical differentiation and on the health of the partnership with United Therapeutics.
Specialty and commercial-stage biopharma
As a smaller commercial-stage biopharma with products like Furoscix, MannKind competes for investor capital and commercial share with numerous specialty pharma and biotech companies pursuing endocrine, cardiovascular, and rare-disease markets. These peers vary widely in pipeline and financial strength and represent alternative, similarly catalyst-driven ways to invest in the theme.
How to invest in MannKind Corporation (MNKD)
There are three common ways to get MNKD exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so MNKD sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where MNKD fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on MannKind Corporation (MNKD)
MannKind is a commercial-stage biopharma whose story rests on growing Tyvaso DPI royalties from United Therapeutics plus its own products Afrezza and Furoscix and a pulmonary pipeline. It rewards successful launches and FDA wins but carries clinical, regulatory, and commercialization risk, so the question is how much higher-risk, catalyst-driven biotech fits your portfolio.
Build a basket around MNKD with Walnut
Use MannKind Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is MNKD a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is growing Tyvaso DPI royalties, a fast-ramping Furoscix launch, Afrezza, and a pulmonary pipeline with 2026 catalysts. The bear case is heavy dependence on Tyvaso DPI, a history of losses, and clinical and regulatory risk typical of smaller biopharma. Treat it as a higher-risk, catalyst-driven position.
What does MannKind actually do?
+
MannKind is a commercial-stage biopharmaceutical company built around its Technosphere dry-powder inhalation platform and endocrine and rare-disease products. It markets Afrezza inhaled insulin and Furoscix for fluid overload, earns royalties from Tyvaso DPI through a United Therapeutics partnership, and develops a pulmonary pipeline. It makes money from product sales and royalties while investing in clinical programs.
Why is Tyvaso DPI so important to MannKind?
+
Tyvaso DPI is a dry-powder inhaled therapy that United Therapeutics markets using MannKind's inhalation technology, and the royalties MannKind earns on its sales have become a major, high-margin revenue stream. Because these royalties grow with limited additional cost as the product expands across pulmonary indications, Tyvaso DPI is central to MannKind's earnings and the durability of its cash flow.
Does MannKind pay a dividend?
+
No. MannKind does not pay a dividend. As a smaller, growth-focused biopharma that has historically run losses and reinvests in launches and its pipeline, it retains cash rather than distributing it. Income is not a reason to hold the stock, and investors should not expect a dividend from a company at this stage of its development.
Is MannKind profitable?
+
Not consistently. MannKind reported a net loss in Q1 2026 even as revenue grew about 15%, because it is investing heavily in commercializing products and advancing its pipeline. It has a history of losses, though growing Tyvaso DPI royalties and product sales are improving the picture. Whether it reaches sustained profitability depends on royalty growth, launch execution, and controlling spending.
What are MannKind's key 2026 catalysts?
+
Key 2026 catalysts include FDA decisions on an Afrezza pediatric indication and a Furoscix autoinjector (ReadyFlow), plus pipeline progress such as readouts for inhaled nintedanib (MNKD-201) in pulmonary fibrosis and development of an inhaled ralinepag with United Therapeutics. These regulatory and clinical events can move the stock meaningfully in either direction, which is typical of catalyst-driven biopharma.
How can I get exposure to MannKind through an ETF?
+
MNKD can appear in some biotech and small-cap ETFs, where it sits among smaller pharma and biotech names, though weightings are typically small. ETF exposure spreads single-stock and clinical risk across many holdings but dilutes how much any MannKind move affects you. Always check a fund's holdings before assuming meaningful exposure to MannKind specifically.
What are the main risks of investing in MNKD?
+
The central risk is concentration: much of the high-margin revenue depends on Tyvaso DPI royalties controlled by partner United Therapeutics. Its own products face commercial, reimbursement, and competitive risk, and the company has a history of losses. Pipeline programs can fail in trials and FDA decisions can go against it, and as a smaller biopharma it carries financing risk. The shares can be volatile around clinical and regulatory events.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with MannKind Corporation's investor relations page or your broker before making investment decisions.